Q1 2024 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc reported a total revenue of $64.5 million in the first quarter of 2024, with a core revenue of $63.2 million driven by precision diagnostics in reproductive health and oncology.
- The company's therapeutic development business, Fulgent Pharma, is making progress with over 30 issued or active patents and a promising lead drug candidate, FID-007, showing positive results in clinical trials for various cancers.
- Fulgent Genetics Inc is experiencing strong momentum in precision diagnostics, expecting approximately 10% sequential core revenue growth for the second quarter.
- The company has launched a new NIPT test, KNOVA, which combines multiple screenings into one test, potentially streamlining processes for physicians and enhancing diagnostic capabilities.
- Fulgent Genetics Inc maintains a strong balance sheet with approximately $846.2 million in cash, cash equivalents, and marketable securities, supporting its strategic initiatives and operational needs.
- Year-over-year, the total revenue decreased slightly from $66.2 million in the first quarter of 2023 to $64.5 million in the first quarter of 2024.
- The company reported a sequential decline in core revenue of about $3.3 million, attributed to timing of biopharma service contracts and a decline in anatomic pathology revenue.
- Fulgent Genetics Inc's gross margin in the first quarter was 34.3%, indicating room for improvement to reach the target of over 40% by the end of the year.
- The company's adjusted EBITDA showed a loss of $3.2 million in the first quarter, although this was an improvement from a loss of $7.2 million in the same quarter the previous year.
- There are uncertainties regarding the impact of finalized lab-developed test regulations, which could potentially affect the company's operations and require adjustments to comply with new FDA guidelines.
Greetings, and welcome to the Fulgent Genetics first-quarter 2024 conference call and webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Melanie Solomon, Investor Relations for Fulgent Genetics. Thank you. You may begin.
Good morning, and welcome to the Fulgent first-quarter 2024 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the Investor Relations section of the company's website www.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
